Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial (VOYAGE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04708145
Recruitment Status : Not yet recruiting
First Posted : January 13, 2021
Last Update Posted : February 23, 2021
Sponsor:
Collaborator:
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Greater Houston Retina Research

Brief Summary:
The VOYAGE trial will assess diabetic retinopathy severity scale (DRSS) levels, through 112 weeks, while being managed with aflibercept as needed, among subjects who completed the 2-year PANORAMA trial (VGFTe-OD-1411) and were treated in a clinical setting prior to joining the VOYAGE study.

Condition or disease Intervention/treatment Phase
Diabetic Retinopathy Drug: Aflibercept Injection Phase 4

Detailed Description:

This phase 4 study is designed to assess the need for ongoing 2 mg intravitreal aflibercept injections (IAI) for subjects who completed the 2-year PANORAMA (VGFTe-OD-1411) trial for the management of diabetic retinopathy (DR). Sites will be considered for VOYAGE if they have 4 or more subjects from PANORAMA able to participate.

Relevant data from all participating subjects will be collected and reported retrospectively for the period between PANORAMA study exit and VOYAGE study enrollment.

For the prospective portion of the study, eyes will be assigned to 1 of 2 groups, eyes without panretinal photocoagulation (PRP) and eyes with PRP.

Group 1: Subjects with study eyes without PRP will be seen every 16 weeks (Q16W) and treated with IAI on a flexible treatment regimen based on their DRSS level. An injection will be given at each 16-week visit when the DRSS level is 47 or worse. If the DRSS level is better than 47, for example level 43 or 35, the study eye will not be treated. DRSS level will be determined by the investigator, based on ophthalmic exam and fundus photography (FP) compared to prior imaging when available.

Every 8 week visits can be performed under specific circumstances:

  • If a subject has a 2-step DRSS level worsening compared to the last protocol-scheduled 16-week visit (for example the week-16 or week-32 visit) and/or the DRSS level is 53 or worse OR
  • If a subject has active proliferative DR (PDR)

Under both of these circumstances, IAI will be administered as scheduled and the subject can be seen and treated every 8 weeks (Q8W) with IAI. Under both of these circumstances, Q8W visits and Q8W IAI treatments can be continued until there is no active PDR and the DRSS improves to the level observed at the visit before the subject began being seen at 8-week intervals.

Group 2: Subjects with study eyes with PRP will be seen Q16W and treated with IAI on a flexible treatment regimen based on activity of the neovascular disease process as assessed by the treating investigator based on ophthalmic exam and/or FP compared to prior imaging when available. If the neovascular disease is inactive, no treatment will be given. If the neovascular disease is active and stable (not new or worse), the subject will be treated with intravitreal (IVT) IAI at the Q16W interval. If new or worsening neovascular disease develops, subjects may be seen and treated Q8W until the neovascular disease is stable or inactive at which time the interval between visits will increase to 16 weeks.

Subjects in both groups will be evaluated for efficacy, using best corrected visual acuity (BCVA) using the 4-meter ETDRS protocol with normal-luminance, Humphrey Visual Field (HVF), National Eye Institute (NEI) Visual Function Questionnaire (VFQ) 25, spectral domain optical coherence tomography (SD-OCT), optical coherence tomography angiography (OCT-A), FP, and fluorescein angiography (FA), and for ocular and systemic safety (including ophthalmic exams and laboratory assessments) through week 112.

Subjects who develop new or worsening PDR, including anterior segment neovascularization (ASNV), or center-involved DME may qualify for rescue treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial
Estimated Study Start Date : June 2021
Estimated Primary Completion Date : June 2023
Estimated Study Completion Date : June 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group 1

Study eyes without PRP from the PANORAMA trial. Subjects will be evaluated every 16 weeks and treated if DRSS level is 47 or worse as determined by the treating investigator.

Subjects may be evaluated every 8 weeks if a 2-step DRSS level worsening compared to the last protocol-scheduled 16-week visit occurs, the DRSS level is 53 or worse, or if a subject has active PDR. Visits can continue every 8 weeks until there is no active PDR, and the DRSS improves to the level observed at the visit before the subject began being seen at 8-week intervals. Thereafter, visits will continue at 16 week intervals.

Drug: Aflibercept Injection
Intravitreal 2mg aflibercept injection
Other Name: Eylea

Experimental: Group 2

Study eyes with PRP from the PANORAMA trial. Subjects will be evaluated every 16 weeks and treated if the neovascular disease process is active and stable (not new or worse) as determined by the treating investigator. If the neovascular disease is inactive, no treatment will be given.

If new or worsening neovascularization develops, subjects may be seen and treated every 8 weeks until the neovascular disease is stable or inactive, at which time the interval between visits will increase to 16 weeks.

Drug: Aflibercept Injection
Intravitreal 2mg aflibercept injection
Other Name: Eylea




Primary Outcome Measures :
  1. DRSS Level Achievement in the VOYAGE study [ Time Frame: 112 weeks ]
    Proportion of subjects achieving a DRSS level of 43 or less in the VOYAGE study.


Secondary Outcome Measures :
  1. DRSS Level Achievement in the PANORAMA study [ Time Frame: 112 weeks ]
    Proportion of subjects achieving a DRSS level of 43 or less from the completion of the PANORAMA study

  2. DRSS Level Improvement [ Time Frame: 112 weeks ]
    Proportion of subjects with stable, worsened, or improved DRSS level from baseline to week 48 and baseline to week 112 compared to the DRSS at the baseline of the VOYAGE trial and the DRSS at the last visit of the PANORAMA trial.

  3. Injection Frequency [ Time Frame: 112 weeks ]
    Mean and median number of IVT aflibercept injections (with and without IAI given for DME)

  4. Subjects without Treatment [ Time Frame: 112 weeks ]
    Proportion of subjects receiving 0 injections

  5. PDR Events [ Time Frame: 112 weeks ]
    Percentage of subjects over time who develop a new PDR event

  6. Center-Involved Diabetic Macular Edema Development [ Time Frame: 112 weeks ]
    Percentage of subjects over time who develop center-involved (CI) DME

  7. Change in Visual Acuity [ Time Frame: 112 weeks ]
    Mean change in ETDRS BCVA from baseline

  8. Change in Central Retinal Thickness [ Time Frame: 112 weeks ]
    Mean change in central retinal thickness from baseline

  9. Change in Area of Nonperfusion [ Time Frame: 112 weeks ]
    Change in total area of retinal capillary non-perfusion from baseline

  10. Changes in Visual Function (HVF) [ Time Frame: 112 weeks ]
    Changes in visual function outcomes from Humphrey Visual Field from baseline

  11. Changes in Visual Function [ Time Frame: 112 weeks ]
    Changes in visual function outcomes NEI VFQ-25 from baseline

  12. Incidence of Adverse Events [ Time Frame: 112 weeks ]
    Incidence and severity of ocular and systemic adverse events from baseline



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Enrolled and completed PANORAMA (VGFTe-OD-1411) clinical trial
  2. Willing and able to comply with clinic visits and study-related procedures
  3. Provide signed informed consent

Exclusion Criteria:

  1. Any prior systemic anti-vascular endothelial growth factor (VEGF) treatment or IVT anti-VEGF treatment in the study eye within 21 days of baseline
  2. Any intra- or periocular corticosteroid treatment in the study eye within 3 months of baseline
  3. Any intraocular sustained-release treatment, implantable device, or gene therapy in the study eye
  4. Pregnant or breastfeeding women
  5. Sexually active men* or women of childbearing potential** who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening/baseline; intrauterine device (IUD); bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly).

    • Contraception is not required for men with documented vasectomy. **Postmenopausal women must be amenorrhoeic for at least 12 months in order not to be considered of childbearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04708145


Contacts
Layout table for location contacts
Contact: Cassie Cone 713-394-7537 cassandra.cone@houstonretina.com
Contact: Melisa Bocanegra 713-524-3434 melisa.bocanegra@houstonretina.com

Sponsors and Collaborators
Greater Houston Retina Research
Regeneron Pharmaceuticals
Additional Information:
Publications:

Layout table for additonal information
Responsible Party: Greater Houston Retina Research
ClinicalTrials.gov Identifier: NCT04708145    
Other Study ID Numbers: VOYAGE
First Posted: January 13, 2021    Key Record Dates
Last Update Posted: February 23, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Retinal Diseases
Diabetic Retinopathy
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Aflibercept
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents